CEO
Genomill Health, Finland
Dr. Manu Tamminen is the Chief Executive Officer and co-founder of Genomill Health, a biotechnology company advancing next-generation molecular diagnostics through innovations in DNA sample preparation and sequencing. With a background in molecular biology and microbial genomics, Dr. Tamminen has focused his career on developing technologies that bridge discovery research and clinical applications. Prior to founding Genomill, he conducted research at the Massachusetts Institute of Technology (MIT) and ETH Zürich, where he specialized in molecular technology development and high-throughput genomics.
At Genomill, Dr. Tamminen leads the development of the company’s proprietary Geno1® technologies, designed to improve the accuracy, efficiency, and scalability of sequencing-based diagnostics. His work centers on making complex genomic workflows more robust and accessible for clinical laboratories.
Dr. Tamminen is passionate about driving the next generation of molecular diagnostics that integrate advanced sequencing with practical, cost-effective laboratory processes. Under his leadership, Genomill Health is building partnerships with diagnostic and sequencing technology leaders across Europe and North America to accelerate the translation of cutting-edge genomics into clinical decision-making.